Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 6,754 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CHANGE Study Clear all

Conditions: Atopic Dermatitis
Interventions: PRN473 (SAR444727), Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Long Beach, California • Los Angeles, California • Miami, Florida + 6 more

Conditions: Spinal Cord Injuries, Obesity, Weight Loss, Diet Modification
Interventions: Portion-Controlled Meals, Enhanced Self-Monitoring, GLB-SCI+; Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Physical Activity, Sedentary Behavior, Gestational Weight Gain, Social Determinants of Health
Interventions: #BabyLetsMove; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 15 Years to 19 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Ovarian Cancer
Interventions: Standard postpartum tubal ligation, Complete Salpingectomy; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Amphetamine-related Disorders
Interventions: contingency management voucher; Behavioral
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Los Angeles, California • Rancho Cucamonga, California

Conditions: Colorectal Neoplasms
Interventions: Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab, Infusional 5-FU/LV with Irinotecan, Oral Capecitabine with Irinotecan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 141
States / cities: Birmgingham, Alabama • Birmingham, Alabama • Birmngham, Alabama + 123 more

Conditions: Lymphoma
Interventions: Vorinostat, Bortezomib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Disease Prevention, Cardiometabolic Diseases, Cardiovascular Risk Factor, Cardiovascular Risk Score, Hypertension, Hyperlipidemia, Diabetes, Lifestyle Modification, Health Coaching
Interventions: Longitudinal, Individualized Health Coaching; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Interventions: Carvedilol; Drug
Lead sponsor: Michele Tagliati, MD; Other
Eligibility: 50 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions: Bleomycin Sulfate, Cisplatin, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Involved-Field Radiation Therapy, Prednisone, Vincristine Sulfate Liposome; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 1,734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 153
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more

Conditions: ALS, Amyotrophic Lateral Sclerosis
Interventions: Autologous Adipose-derived Mesenchymal Stromal Cells; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Complex Abdominal Aortic Aneurysm, Juxtarenal Aortic Aneurysm, Pararenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm
Interventions: Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: San Diego, California

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more

Conditions: Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
Interventions: Vorolanib, Nivolumab; Drug · Biological
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Palo Alto, California • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Prediabetes, Metabolic Syndrome
Interventions: GLB Group, GLB DVD; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide; Drug
Lead sponsor: Emory University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Asthma
Interventions: Benralizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more

Conditions: Obesity, Overweight and Obesity, Quality of Life, Health Behavior
Interventions: Noom Healthy Weight; Behavioral
Lead sponsor: Noom Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 370 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemorrhagic Fever, Ebola
Interventions: Ad26.ZEBOV, MVA-BN-Filo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 0 Years to 71 Years
Enrollment: 677 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Cancer, Anxiety
Interventions: Health Education Program, CBT Mobile Application; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: LY2216684, Fluoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Parkinson's Disease
Interventions: Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID; Drug
Lead sponsor: Biotie Therapies Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more

Conditions: Head and Neck Cancer, Pain, Lung Cancer, Esophageal Cancer
Interventions: Telephone-Based Intervention, Questionnaire Administration; Behavioral · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Solid Tumor, Adult, Refractory Cancer, Recurrent Cancer, Cancer
Interventions: IMA202 Product, IMADetect®; Drug · Device
Lead sponsor: Immatics US, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Houston, Texas

Search by objective public record fields.

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

Building an Evidence Base for Weight Loss Strategies Among Those With Chronic SCI-The GLB-SCI+

Teen Mom Study Feasibility Trial

Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)

Long-term Behavior Change - 1

Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Preventative Screening and Health Coaching in a Food Insecure Population

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

Physician Modified Endograft For Complex Aortic Aneurysm Repair

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Evaluation of Group Lifestyle Balance DVD in Primary Care Practice

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

Improving Quality of Life in Men and Women With Overweight or Obesity

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Mobile App of CBT for Anxiety and Cancer

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy

TCR-engineered T Cells in Solid Tumors: IMA202-101